Hepatobiliary effects and safety of tirzepatide: A systematic review and meta‐analysis.

The article "Hepatobiliary effects and safety of tirzepatide: A systematic review and meta-analysis" published in Diabetes, Obesity & Metabolism explores the impact of tirzepatide on metabolic-dysfunction-associated steatotic liver disease (MASLD). The study found that tirzepatide treatment led to significant reductions in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared to placebo and insulin. Additionally, tirzepatide showed promising results in reducing liver fat content and had a comparable safety profile to other treatment options. The authors recommend further research with longer follow-up durations to better understand tirzepatide's potential as a therapeutic strategy for MASLD. [Extracted from the article]